Skip to main content

Table 5 Bayesian method estimates of indirect probabilities of passing different visual acuity thresholds at month 1 for patients with BRVO

From: Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

Improvement or worsening at month 1

Probability for Group§ (95% CrI)

Relative risk* (95% CrI)

 

Ranibizumab

Dexamethasone

 

Gain ≥20 letters

0.191 (0.130, 0.261)

0.093 (0.027,0.213)

0.49 (0.16, 1.45)

Gain ≥10 letters and <20 letters

0.309 (0.235,0.389)

0.366 (0.221, 0.511)

1.19 (0.73, 1.92)

Loss <10 letters and gain <10 letters

0.478 (0.395, 0.561)

0.436 (0.282, 0.579)

0.91 (0.62, 1.35)

Loss ≥10 letters and <20 letters

0.015 (0.002,0.041)

0.028 (0.000, 0.133)

1.93 (0.10, 39.13)

Loss ≥20 letters

0.007 (0.000, 0.027)

0.077 (0.001,0.339)

10.47 (0.46, 237.71)

  1. §Mean of 100000 samples from posterior distributions of probability for change in BCVA from baseline category.
  2. *Ratio of mean probabilities with credible interval based on Delta method on log scale.
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us